1 |
Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med 2021;10:4219. [PMID: 34575330 DOI: 10.3390/jcm10184219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Olbei M, Thomas JP, Hautefort I, Treveil A, Bohar B, Madgwick M, Gul L, Csabai L, Modos D, Korcsmaros T. CytokineLink: A Cytokine Communication Map to Analyse Immune Responses-Case Studies in Inflammatory Bowel Disease and COVID-19. Cells 2021;10:2242. [PMID: 34571891 DOI: 10.3390/cells10092242] [Reference Citation Analysis]
|
3 |
Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Reference Citation Analysis]
|
4 |
Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
|
5 |
Pugliese D, Privitera G, Fiorani M, Parisio L, Calvez V, Papa A, Gasbarrini A, Armuzzi A. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therap Adv Gastroenterol 2022;15:17562848221102283. [PMID: 35721840 DOI: 10.1177/17562848221102283] [Reference Citation Analysis]
|
6 |
Wlazło M, Kierkuś J. Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature. JCM 2022;11:2004. [DOI: 10.3390/jcm11072004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|